Preventing HIV infection without targeting the virus: How reducing HIV target cells at the genital tract is a new approach to HIV prevention

AIDS Research and Therapy

Volumn 14, Issue 1, 2017, Pages

  Lajoie, Julie ^a,b   Mwangi, Lucy ^b   Fowke, Keith R ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

Highly exposed seronegative (HESN); HIV; Immune activation; Immune quiescence; Protection

Indexed keywords

ACETYLSALICYLIC ACID; CD4 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR5; HYDROXYCHLOROQUINE; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; L SELECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; VASCULAR CELL ADHESION MOLECULE 1;

DISEASE TRANSMISSION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; NONHUMAN; POPULATION RISK; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SERODIAGNOSIS; T LYMPHOCYTE; VIRUS IMMUNITY; VIRUS TRANSMISSION; CYTOLOGY; DISEASE PREDISPOSITION; DRUG EFFECTS; FEMALE; FEMALE GENITAL SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INNATE IMMUNITY; KENYA; MUCOSAL IMMUNITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEX WORKER; VIROLOGY;

ASPIRIN; DISEASE SUSCEPTIBILITY; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; HYDROXYCHLOROQUINE; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; KENYA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX WORKERS;

EID: 85029222849     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/s12981-017-0166-7     Document Type: Review

References (33)

1. UNAIDS. Global aids up date 2016; 2016. p. 1-16.
2. Card CM, Ball TB, Fowke KR. Immune quiescence: a model of protection against HIV infection. Retrovirology. 2013;10:141.
3. Corbett EL, Steketee RW, ter Kuile FO, Latif AS, Kamali A, Hayes RJ. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet. 2002;359:2177-87.
4. Johnson CC, Jones EH, Goldberg M, Asbel LE, Salmon ME, Waller CL. Screening for Chlamydia trachomatis and Neisseria gonorrhoeae among adolescents in Family Court, Philadelphia, Pennsylvania. Sex Transm Dis. 2008;35:S24-7.
5. Plummer FA. Heterosexual transmission of human immunodeficiency virus type 1 (HIV): interactions of conventional sexually transmitted diseases, hormonal contraception and HIV-1. AIDS Res Hum Retrovir. 1998;14(Suppl 1):S5-10.
6. Feinen B, Jerse AE, Gaffen SL, Russell MW. Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection. Mucosal Immunol. 2010;3:312-21.
7. Liu Y, Feinen B, Russell MW. New concepts in immunity to Neisseria gonorrhoeae: innate responses and suppression of adaptive immunity favor the pathogen, not the host. Front Microbiol. 2011;2:52.
8. Elhed A, Unutmaz D. Th17 cells and HIV infection. Curr Opin HIV AIDS. 2010;5:146-50.
9. Masson L, Mlisana K, Little F, Werner L, Mkhize NN, Ronacher K, et al. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sex Transm Infect. 2014;90:580-7.
10. Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS. 2007;21:589-98.
11. Richardson BA, Lavreys L, Martin HL, Stevens CE, Ngugi E, Mandaliya K, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis. 2001;28:394-400.
12. Lozenski K, Ownbey R, Wigdahl B, Kish-Catalone T, Krebs FC. Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety. BMC Pharmacol Toxicol. 2012;13:9.
13. Zhong M, He B, Yang J, Bao R, Zhang Y, Zhou D, et al. L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide. Antimicrob Agents Chemother. 2012;56:3121-32.
14. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis. 2001;184:418-28.
15. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74.
16. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, et al. Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis. 2012;206:993-1001.
17. Passmore J-AS, Jaspan HB, Masson L. Genital inflammation, immune activation and risk of sexual HIV acquisition. Curr Opin HIV AIDS. 2016;11:156-62.
18. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012;206:258-66.
19. Huang Y, Duerr A, Frahm N, Zhang L, Moodie Z, De Rosa S, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study. PLoS ONE. 2014;9:e108631-11.
20. Piacentini L, Fenizia C, Naddeo V, Clerici M. Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine. 2008;26:3002-7.
21. Horton RE, McLaren PJ, Fowke K, Kimani J, Ball TB. Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations. J Infect Dis. 2010;202(Suppl 3):S377-81.
22. Mackelprang RD, Baeten JM, Donnell D, Celum C, Farquhar C, de Bruyn G, et al. Quantifying ongoing HIV-1 exposure in HIV-1-serodiscordant couples to identify individuals with potential host resistance to HIV-1. J Infect Dis. 2012;206:1299-308.
23. Fowke KR, Nagelkerke NJ, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet. 1996;348:1347-51.
24. McKinnon LR, Izulla P, Nagelkerke N, Munyao J, Wanjiru T, Shaw SY, et al. Risk factors for HIV acquisition in a prospective Nairobi-based female sex worker cohort. AIDS Behav. 2015;19:2204-13.
25. McLaren PJ, Ball TB, Wachihi C, Jaoko W, Kelvin DJ, Danesh A, et al. HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors. J Infect Dis. 2010;202:S339-44.
26. Songok EM, Luo M, Liang B, Mclaren P, Kaefer N, Apidi W, et al. Microarray analysis of HIV resistant female sex workers reveal a gene expression signature pattern reminiscent of a lowered immune activation state. PLoS ONE. 2012;7:e30048.
27. Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, Fowke KR. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells. J Infect Dis. 2009;199:1318-22.
28. Lajoie J, Juno J, Burgener A, Rahman S, Mogk K, Wachihi C, et al. A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers. Mucosal Immunol. 2012;5:277-87.
29. Burgener A, Rahman S, Ahmad R, Lajoie J, Ramdahin S, Mesa C, et al. Comprehensive proteomic study identifies serpin and cystatin antiproteases as novel correlates of HIV-1 resistance in the cervicovaginal mucosa of female sex workers. J Proteome Res. 2011;10:5139-49.
30. Koning FA, Otto SA, Hazenberg MD, Dekker L, Prins M, Miedema F, et al. Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol. 2005;175:6117-22.
31. Jennes W, Evertse D, Borget M-Y, Vuylsteke B, Maurice C, Nkengasong JN, et al. Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin Exp Immunol. 2006;143:435-44.
32. Thibodeau V, Fourcade L, Labbé A-C, Alary M, Guédou F, Poudrier J, et al. Highly-exposed HIV-1 seronegative female commercial sex workers sustain in their genital mucosa increased frequencies of tolerogenic myeloid and regulatory T-cells. Sci Rep. 2017;7:43857.
33. Lajoie J, Poudrier J, Massinga-Loembe M, Guédou F, Agossa-Gbenafa C, Labbé A-C, et al. Differences in immunoregulatory cytokine expression patterns in the systemic and genital tract compartments of HIV-1-infected commercial sex workers in Benin. Mucosal Immunol. 2008;1:309-16.